Logo

Swift Biosciences SARS-CoV-2 Research Panel

May 04, 2020

Swift Biosciences has released a research-use targeted sequencing panel for SARS-CoV-2. The amplicon-based multiplex panel targets the full 30 kb viral genome in a single tube, two-hour workflow with two rounds of PCR. More than three hundred primer pairs help increase sensitivity and specificity due to the higher probability of amplifying limited quantities of viral template material, as does the ability to use sequencing to confirm that reads are mappable to SARS-CoV-2 instead of similar coronaviruses or pathogens, the company said. Swift's workflow also adds sequencing adapters directly without the need for a secondary library construction.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.